There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vericel Corp (VCEL) and Alexion Pharmaceuticals (ALXN) with bullish sentiments.
Vericel Corp (VCEL)
Vericel Corp received a Buy rating and a $23 price target from Oppenheimer analyst Kevin Degeeter today. The company’s shares opened today at $17.10, close to its 52-week high of $18.87.
Degeeter commented:
“Initiating coverage of Outperform rating and $23 PT. We view VCEL as a specialty products company with: 1) strong commercial acumen demonstrated by execution of MACI launch strategy and expansion of knee cartilage repair market; 2) extensive regulatory and manufacturing expertise with cellular therapies; and 3) potential for significant operating leverage based on an integrated commercial model. Our Outperform rating is based primarily on potential to expand the cartilage repair market, particularly in patella defects, resulting in potential upside to Street revenue consensus. Furthermore, while we cannot predict the timing or focus of future business development, in our view, an expanded product portfolio could leverage VCEL’s core strength in selling specialty products for orthopedics and sports medicine.”
According to TipRanks.com, Degeeter is a 4-star analyst with an average return of 15.4% and a 50.0% success rate. Degeeter covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences Inc, Molecular Templates Inc, and Neon Therapeutics Inc.
Currently, the analyst consensus on Vericel Corp is a Strong Buy with an average price target of $21.10.
See today’s analyst top recommended stocks >>
Alexion Pharmaceuticals (ALXN)
In a report released today, Hartaj Singh from Oppenheimer assigned a Buy rating to Alexion Pharmaceuticals. The company’s shares opened today at $119.87.
According to TipRanks.com, Singh is a 3-star analyst with an average return of 0.9% and a 42.2% success rate. Singh covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Strongbridge Biopharma Plc, and Syndax Pharmaceuticals Inc.
Currently, the analyst consensus on Alexion Pharmaceuticals is a Strong Buy with an average price target of $165.71, a 38.2% upside from current levels. In a report issued on January 22, Piper Jaffray also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
